Showing results (251-260 of 283) with videos related to

Sort By:
Pageof 29
The Lancet. Oncology|April 3, 2025
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trialToon Van Gorp, Kathleen N Moore, Gottfried E Konecny, et al.
The Lancet. Oncology|July 31, 2025
ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025Nicole Concin, Xavier Matias-Guiu, David Cibula, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2023
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial CancerIgnace Vergote, Jose Alejandro Pérez-Fidalgo, Erika Paige Hamilton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2020
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary PeritoneumBradley J Monk, Rachel N Grisham, Susana Banerjee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without <i>BRCA</i> MutationPanagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 2, 2026
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapyMatthew A Powell, Sharad Ghamande, Lars C Hanker, et al.
American Journal of Obstetrics and Gynecology|August 30, 2021
Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment StudyGloria Salvo, Pedro T Ramirez, Mario M Leitao, et al.
American Journal of Obstetrics and Gynecology|June 19, 2023
Survival associated with extent of radical hysterectomy in early-stage cervical cancer: a subanalysis of the Surveillance in Cervical CANcer (SCCAN) collaborative studyNicolò Bizzarri, Denis Querleu, Lukáš Dostálek, et al.
Nature Communications|April 17, 2026
NKG2A inhibition promotes NK cell-CD8<sup>+</sup> T cell interactions to improve anticancer immunity in ovarian carcinomaTereza Lanickova, Artemis Angelidou, Michal Hensler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2023
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 StudyIgnace Vergote, Els Van Nieuwenhuysen, Roisin E O'Cearbhaill, et al.
Pageof 29